Where Will CymaBay Therapeutics Inc (CBAY) Stock Go Next After It Is Higher By 23.94% in a Week?

Friday, December 02, 2022 03:56 PM | InvestorsObserver Analysts

Mentioned in this article

Where Will CymaBay Therapeutics Inc (CBAY) Stock Go Next After It Is Higher By 23.94% in a Week?

The market has been high on CymaBay Therapeutics Inc (CBAY) stock recently. CBAY gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CymaBay Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CBAY!

See Full CBAY Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CBAY Stock Today?

CymaBay Therapeutics Inc (CBAY) stock is higher by 3.42% while the S&P 500 is down -0.35% as of 3:44 PM on Friday, Dec 2. CBAY has gained $0.13 from the previous closing price of $3.95 on volume of 1,003,787 shares. Over the past year the S&P 500 is down -9.99% while CBAY has gained 18.55%. CBAY lost -$1.25 per share in the over the last 12 months. To screen for more stocks like CymaBay Therapeutics Inc click here.

More About CymaBay Therapeutics Inc

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta. Click Here to get the full Stock Report for CymaBay Therapeutics Inc stock.